Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
We take a look at several key developments in myeloma on the antibody and cell therapy front.
An upcoming small biotech focused on IO targets with their novel platform approach
Some examples of potentially useful biomarker inclusion in early oncology trials
Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
We offer 13 key highlights from day 2 of ASH18, including some surprises.
Highlights from Day 1 of the 2018 ASH conference held in San Diego
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
What to watch out for in the ASH18 LBA session
A top-line review of the ASH18 abstract palooza